Health care analysts predict the global hepatitis diagnostics market will reach up to $6.9 billion by 2025, a recent press release from Grand View Research reports. 

The growth is attributable to a rapid rise in testing, awareness and treatment for hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) around the world. Analysts say the burden of viral hepatitis has also significantly increased over the past decade. 

Key findings from the report suggest hepatitis blood tests will dominate the market and see the fastest growth, thanks to their growing adoption as a first line of hepatitis diagnosis. Liver function tests are also expected to take over a large share of the market, since they’re often a prerequisite for further analytical examinations.

Last year, North America represented the largest hepatitis diagnostic market, owing to rising prevalence, heightened awareness and a developed health care infrastructure. Experts also say Asia Pacific is expected to witness rapid growth in hepatitis testing by 2025, owing to a continued rise in new cases.

Major players in the arena will likely include Abbott Laboratories, Roche, Bio Rad Laboratories and Siemens.